AVEO PHARMACEUTICALS, INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2010 to Q3 2022

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Aveo Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2010 to Q3 2022.
  • Aveo Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2022 was -$3.27M, a 68.5% increase year-over-year.
  • Aveo Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2022 was -$29M, a 49.6% increase year-over-year.
  • Aveo Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$53.3M, a 49.9% decline from 2020.
  • Aveo Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2020 was -$35.6M, a 479% decline from 2019.
  • Aveo Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2019 was $9.39M.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2022 -$29M -$3.27M +$7.1M +68.5% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-07
Q2 2022 -$36.1M -$8.32M +$5.28M +38.8% Apr 1, 2022 Jun 30, 2022 10-Q 2022-11-07
Q1 2022 -$41.4M -$10.2M +$11.9M +53.9% Jan 1, 2022 Mar 31, 2022 10-Q 2022-11-07
Q4 2021 -$53.3M -$7.26M +$4.25M +36.9% Oct 1, 2021 Dec 31, 2021 10-K 2022-03-14
Q3 2021 -$57.6M -$10.4M -$1.98M -23.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$55.6M -$13.6M -$6.29M -86.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-07
Q1 2021 -$49.3M -$22.1M -$13.7M -164% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-07
Q4 2020 -$35.6M -$11.5M -$7.04M -158% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-14
Q3 2020 -$28.5M -$8.39M -$24.8M -151% Jul 1, 2020 Sep 30, 2020 10-K 2022-03-14
Q2 2020 -$3.72M -$7.31M -$4.17M -133% Apr 1, 2020 Jun 30, 2020 10-K 2022-03-14
Q1 2020 $452K -$8.38M -$8.94M -1610% Jan 1, 2020 Mar 31, 2020 10-K 2022-03-14
Q4 2019 $9.39M -$4.46M -$26.3M -120% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-16
Q3 2019 $35.7M $16.4M +$38.6M Jul 1, 2019 Sep 30, 2019 10-K 2021-03-16
Q2 2019 -$2.93M -$3.14M -$7.14M -178% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-16
Q1 2019 $4.21M $555K +$9.54M Jan 1, 2019 Mar 31, 2019 10-K 2021-03-16
Q4 2018 -$5.33M $21.8M +$18.3M +524% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-16
Q3 2018 -$23.6M -$22.2M +$4.23M +16% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-16
Q2 2018 -$27.9M $4M +$37.3M Apr 1, 2018 Jun 30, 2018 10-K 2020-03-16
Q1 2018 -$65.2M -$8.99M -$148K -1.67% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-16
Q4 2017 -$65M $3.5M +$9.1M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-14
Q3 2017 -$74.1M -$26.4M -$21.4M -432% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-14
Q2 2017 -$52.7M -$33.3M -$24.7M -287% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-14
Q1 2017 -$28M -$8.84M -$1.13M -14.7% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-14
Q4 2016 -$26.9M -$5.61M +$980K +14.9% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-13
Q3 2016 -$27.9M -$4.97M -$12.9M -163% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-13
Q2 2016 -$15M -$8.61M -$3.15M -57.7% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-13
Q1 2016 -$11.8M -$7.71M +$3.16M +29.1% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-13
Q4 2015 -$15M -$6.59M +$7.31M +52.6% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-22
Q3 2015 -$22.3M $7.91M +$22.4M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-22
Q2 2015 -$44.7M -$5.46M +$12.5M +69.6% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-22
Q1 2015 -$57.2M -$10.9M -$4.42M -68.6% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-22
Q4 2014 -$52.7M -$13.9M +$2.83M +16.9% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-15
Q3 2014 -$55.6M -$14.4M +$9.87M +40.6% Jul 1, 2014 Sep 30, 2014 10-K 2016-03-15
Q2 2014 -$65.4M -$18M +$14M +43.7% Apr 1, 2014 Jun 30, 2014 10-K 2016-03-15
Q1 2014 -$79.4M -$6.45M +$27.6M +81.1% Jan 1, 2014 Mar 31, 2014 10-K 2016-03-15
Q4 2013 -$107M -$16.7M +$4.76M +22.1% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-06
Q3 2013 -$112M -$24.3M +$5.82M +19.3% Jul 1, 2013 Sep 30, 2013 10-K 2015-03-06
Q2 2013 -$118M -$31.9M -$2.37M -8.01% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-06
Q1 2013 -$115M -$34.1M -$839K -2.52% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-06
Q4 2012 -$114M -$21.5M +$3.69M +14.7% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-13
Q3 2012 -$118M -$30.1M -$6.3M -26.5% Jul 1, 2012 Sep 30, 2012 10-K 2014-03-13
Q2 2012 -$112M -$29.5M -$23.8M -416% Apr 1, 2012 Jun 30, 2012 10-K 2014-03-13
Q1 2012 -$88M -$33.2M -$119M -139% Jan 1, 2012 Mar 31, 2012 10-K 2014-03-13
Q4 2011 $30.6M -$25.2M Oct 1, 2011 Dec 31, 2011 10-K 2013-03-11
Q3 2011 -$23.8M -$5.21M -28% Jul 1, 2011 Sep 30, 2011 10-K 2013-03-11
Q2 2011 -$5.73M +$9.76M +63% Apr 1, 2011 Jun 30, 2011 10-K 2013-03-11
Q1 2011 $85.4M Jan 1, 2011 Mar 31, 2011 10-K 2013-03-11
Q3 2010 -$18.6M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-08
Q2 2010 -$15.5M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.